How does OncuraKit compare to Galleri by Grail?

OncuraKit and Galleri are both multi-cancer early detection (MCED) tests but differ fundamentally in technology, sample type, sensitivity, and result type. OncuraKit: urine sample, no prescription required, no blood draw, measures 3 miRNA markers using single-molecule nanopore detection (no amplification), achieves 81–97% Stage I/II sensitivity per marker, produces binary YES/NO results, zero data overlap between cancer and healthy populations, $995. Galleri: blood draw required, prescription required, measures cfDNA methylation patterns using PCR + machine learning, achieves 16.8% Stage I sensitivity, produces a probabilistic cancer signal score ('signal detected'), significant data overlap requiring score-based interpretation, approximately $950. The key clinical difference is Stage I sensitivity: OncuraKit detects early-stage cancer far more reliably — the period when treatment is most curative.